The report “Investigation Report on China Enoxaparin Sodium Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact email@example.com with Research Report on Investigation Report on China Enoxaparin Sodium Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.
The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Enoxaparin Sodium Market, 2009-2018”On chinamarketresearchreports.com . Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly onefourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll. Heparin drugs are widely used in hemodialysis and various surgical operations. Because lowmolecularweight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Lowmolecularweight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of lowmolecularweight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993...
Please join StudyMode to read the full document